Alpha-lactalbumin vaccine - Anixa Biosciences/Cleveland Clinic
Alternative Names: Breast cancer vaccine - Anixa BiosciencesLatest Information Update: 07 May 2026
At a glance
- Originator Cleveland Clinic
- Developer Anixa Biosciences; Cleveland Clinic
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Triple negative breast cancer
Most Recent Events
- 29 Apr 2026 Anixa Biosciences has patent protection for breast cancer vaccine technology in Mexico
- 06 Apr 2026 Anixa Biosciences completes phase-0 trial in Triple-negative-breast cancer in USA (SC) (NCT04674306)
- 09 Mar 2026 The Korean Ministry of Intellectual Property (MOIP) issues a Notice of Allowance for a patent related to breast cancer vaccine technology